Cyanosis occurs in about one-third of potentially fatal forms of congenital heart disease (TBS). Early recognition, resuscitation, and transport to an appropriate cardiovascular care center are important for the survival of neonates with cyanosis.

Neonates with cyanosis require immediate evaluation, general supportive care to maintain adequate tissue perfusion and oxygenation, and specific treatment when the underlying cause is known. Specific interventions for cyanotic congenital heart disease (CCH) of the newborn include administration of prostaglandin E1 (PGE1; also known as alprostadil) and catheter-based corrective or palliative procedures.